EDIT Editas Medicine Inc.

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.

Webinar Presentation Details:

The live and archived webcast of the Company’s webinar presentation will be accessible through this , or through the page of the “Investors” section of the Company’s website.

A replay of the webinar will be available upon conclusion of the webinar in the Investors section of the Editas Medicine website at .

About Editas Medicine 

As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit  



Investor and Media Contacts: 
  
EN
28/08/2025

Underlying

EDITEditas Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Editas Medicine Inc.

 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Ca...

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate. Webinar Presentation Details:The live and archived webcast of the Company’s webinar presentation will be accessible through this , or through the page of the “Inv...

9h / 48m 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare ConferenceFormat: One-on-one MeetingsDate: Wednesday, September 3Location: Boston, MA Cantor Global Healthcare ConferenceFormat: Fireside Chat with Webcast and One-on-one MeetingsDate: Thursday, Septembe...

August 27, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Second Quarter 2025 Results and Business Upd...

Editas Medicine Announces Second Quarter 2025 Results and Business Updates Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Presented data at ASGCT, TIDES, and EHA that validate differentiated potential of Editas’ gene upregulation strategy and in vivo delivery platform technology ​ Strong cash position with operational runway into the se...

August 12, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delive...

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIR...

June 12, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistr...

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene ...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch